BioSpace News Archive

Helix, a nationwide leader in population genomics, COVID-19 diagnostic testing and viral surveillance, has received FDA Emergency Use Authorization (EUA) for its SARS-CoV-2 Test and Helix COVID-19 Self-Collection Kit for use in a secure ‘Locker System’ – the first and only SARS-CoV-2 test authorized for use with a self-service test-retrieval system.

The National Eczema Association announces it has been awarded a competitive grant from Pfizer in the amount of $175K to support its novel research study titled “Atopic Dermatitis Flares – An Understanding and Definition from the Patient Perspective.” The grant period commenced in January 2022 with a timeline of 18 months.

Bristol Myers Squibb announced that the European Commission has granted Marketing Authorization for Breyanzi, a CD19-directed chimeric antigen receptor T cell immunotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B after two or more lines of systemic therapy.

To enhance around-the-clock monitoring of post-acute cardiopulmonary residents, New York’s Momentum at South Bay for Rehabilitation and Nursing partnered with Murata Vios, Inc. to deploy the Vios Monitoring System.

Endovascular Engineering, a privately-held developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis and Pulmonary Embolism, announced the closing of a $15 million Series A1 financing.

ChemImage, a leader in molecular chemical imaging, announced the appointment of Adam Saltman, MD, PhD as its Chief Medical Officer.

Pressure BioSciences, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2021, provided a business update, and offered guidance on the Company’s strategic changes and growth acceleration planned for FY 2022.

TheraCell Inc., a leading allograft solution company, announced that it has been acquired by Isto Biologics, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies.

Tevogen Bio announced the strategic expansion of its leadership team with two new executives to support the biotech’s rapid operational growth, manufacturing readiness, and the continued development and utilization of its next generation precision T cell platform technology.

Rising burden of chronic diseases across the globe and growing geriatric population are some key factors driving the global healthcare distribution market revenue growth.